162 related articles for article (PubMed ID: 19259664)
1. Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack.
Okroj M; Corrales L; Stokowska A; Pio R; Blom AM
Cancer Immunol Immunother; 2009 Nov; 58(11):1771-80. PubMed ID: 19259664
[TBL] [Abstract][Full Text] [Related]
2. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
Niehans GA; Cherwitz DL; Staley NA; Knapp DJ; Dalmasso AP
Am J Pathol; 1996 Jul; 149(1):129-42. PubMed ID: 8686736
[TBL] [Abstract][Full Text] [Related]
3. Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors.
Okroj M; Hsu YF; Ajona D; Pio R; Blom AM
Mol Immunol; 2008 Jan; 45(1):169-79. PubMed ID: 17548110
[TBL] [Abstract][Full Text] [Related]
4. Immunization against tumor cell surface complement-regulatory proteins.
Durrant LG; Spendlove I
Curr Opin Investig Drugs; 2001 Jul; 2(7):959-66. PubMed ID: 11757799
[TBL] [Abstract][Full Text] [Related]
5. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.
Ravindranath NM; Shuler C
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Feb; 103(2):231-9. PubMed ID: 17234541
[TBL] [Abstract][Full Text] [Related]
6. Expression of complement restriction factors (CD46, CD55 & CD59) in head and neck squamous cell carcinomas.
Ravindranath NM; Shuler C
J Oral Pathol Med; 2006 Oct; 35(9):560-7. PubMed ID: 16968237
[TBL] [Abstract][Full Text] [Related]
7. Primary human hepatocytes are protected against complement by multiple regulators.
Halme J; Sachse M; Vogel H; Giese T; Klar E; Kirschfink M
Mol Immunol; 2009 Jul; 46(11-12):2284-9. PubMed ID: 19446335
[TBL] [Abstract][Full Text] [Related]
8. Expression of complement regulatory proteins on human natural killer cell subsets.
Wang L; Halliday D; Johnson PM; Christmas SE
Immunol Lett; 2007 Oct; 112(2):104-9. PubMed ID: 17719652
[TBL] [Abstract][Full Text] [Related]
9. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59.
Clayton A; Harris CL; Court J; Mason MD; Morgan BP
Eur J Immunol; 2003 Feb; 33(2):522-31. PubMed ID: 12645951
[TBL] [Abstract][Full Text] [Related]
10. Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy.
Livingston PO; Hood C; Krug LM; Warren N; Kris MG; Brezicka T; Ragupathi G
Cancer Immunol Immunother; 2005 Oct; 54(10):1018-25. PubMed ID: 15926079
[TBL] [Abstract][Full Text] [Related]
11. Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma.
Macor P; Mezzanzanica D; Cossetti C; Alberti P; Figini M; Canevari S; Tedesco F
Cancer Res; 2006 Apr; 66(7):3876-83. PubMed ID: 16585216
[TBL] [Abstract][Full Text] [Related]
12. The C-terminus of complement factor H is essential for host cell protection.
Józsi M; Oppermann M; Lambris JD; Zipfel PF
Mol Immunol; 2007 Apr; 44(10):2697-706. PubMed ID: 17208302
[TBL] [Abstract][Full Text] [Related]
13. Complement inhibitor membrane cofactor protein (MCP; CD46) is constitutively shed from cancer cell membranes in vesicles and converted by a metalloproteinase to a functionally active soluble form.
Hakulinen J; Junnikkala S; Sorsa T; Meri S
Eur J Immunol; 2004 Sep; 34(9):2620-9. PubMed ID: 15307194
[TBL] [Abstract][Full Text] [Related]
14. The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells.
Kodym E; Kodym R; Reis AE; Habib AA; Story MD; Saha D
Lung Cancer; 2009 Oct; 66(1):37-47. PubMed ID: 19193471
[TBL] [Abstract][Full Text] [Related]
15. CD59 efficiently protects human NT2-N neurons against complement-mediated damage.
Pedersen ED; Aass HC; Rootwelt T; Fung M; Lambris JD; Mollnes TE
Scand J Immunol; 2007; 66(2-3):345-51. PubMed ID: 17635812
[TBL] [Abstract][Full Text] [Related]
16. Complement regulator loss on apoptotic neuronal cells causes increased complement activation and promotes both phagocytosis and cell lysis.
Cole DS; Hughes TR; Gasque P; Morgan BP
Mol Immunol; 2006 May; 43(12):1953-64. PubMed ID: 16406094
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth.
Ajona D; Hsu YF; Corrales L; Montuenga LM; Pio R
J Immunol; 2007 May; 178(9):5991-8. PubMed ID: 17442984
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic inhibition of the complement system.
Makrides SC
Pharmacol Rev; 1998 Mar; 50(1):59-87. PubMed ID: 9549758
[TBL] [Abstract][Full Text] [Related]
19. High-density rafts preferentially host the complement activator measles virus F glycoprotein but not the regulators of complement activation.
Ghannam A; Hammache D; Matias C; Louwagie M; Garin J; Gerlier D
Mol Immunol; 2008 Jun; 45(11):3036-44. PubMed ID: 18455798
[TBL] [Abstract][Full Text] [Related]
20. Co-expression of alpha(1,3)galactosyltransferase and Bacillus thuringiensis PIPLC enhances hyperacute rejection of tumor cells.
Hellrung DJ; Kisselev S; Link CJ
Cancer Immunol Immunother; 2007 Jan; 56(1):25-34. PubMed ID: 16612594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
